1. Home
  2. ECL vs ARGX Comparison

ECL vs ARGX Comparison

Compare ECL & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ecolab Inc.

ECL

Ecolab Inc.

HOLD

Current Price

$281.30

Market Cap

77.5B

ML Signal

HOLD

Logo argenx SE

ARGX

argenx SE

HOLD

Current Price

$818.91

Market Cap

52.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ECL
ARGX
Founded
1923
2008
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Package Goods/Cosmetics
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
77.5B
52.6B
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
ECL
ARGX
Price
$281.30
$818.91
Analyst Decision
Buy
Strong Buy
Analyst Count
15
19
Target Price
$295.00
$979.22
AVG Volume (30 Days)
1.0M
353.9K
Earning Date
02-10-2026
02-26-2026
Dividend Yield
1.04%
N/A
EPS Growth
N/A
N/A
EPS
6.95
23.27
Revenue
$15,890,400,000.00
$3,683,281,000.00
Revenue This Year
$3.04
$91.44
Revenue Next Year
$6.03
$36.90
P/E Ratio
$40.51
$32.78
Revenue Growth
1.38
92.98
52 Week Low
$221.62
$510.06
52 Week High
$286.04
$934.62

Technical Indicators

Market Signals
Indicator
ECL
ARGX
Relative Strength Index (RSI) 66.79 46.64
Support Level $271.22 $781.07
Resistance Level $282.47 $818.78
Average True Range (ATR) 4.97 24.70
MACD 1.09 3.55
Stochastic Oscillator 94.75 73.52

Price Performance

Historical Comparison
ECL
ARGX

About ECL Ecolab Inc.

Ecolab produces and markets cleaning and sanitation products for the industrial manufacturing, hospitality, healthcare, and life sciences markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. Additionally, Ecolab sells customized water management solutions across its end markets. The company has a strong hold on the US market and is growing its presence abroad.

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Share on Social Networks: